stockportfolio.pro
Stocks / BCRX vs RARE
BCRX vs RARE
BioCryst Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioCryst Pharmaceuticals, Inc. (BCRX) | Ultragenyx Pharmaceutical Inc. (RARE) | |
|---|---|---|
| Market cap | $2.1B | $2.3B |
| Revenue (latest FY) | $874.84M | $673.00M |
| Net income (latest FY) | $263.86M | $-575.00M |
| Revenue growth (5y CAGR) | 117.9% | 19.9% |
| Net margin | 30.2% | -85.4% |
| Return on equity | -221.4% | 718.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BCRX — free Open RARE — freeFrequently asked questions
Which is bigger, BCRX or RARE?
Ultragenyx Pharmaceutical Inc. is larger by market capitalization — $2.3B versus $2.1B.
Which grows faster, BCRX or RARE?
Over the last five fiscal years, BioCryst Pharmaceuticals, Inc. grew revenue faster — 117.9%/yr versus 19.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.